When the interaction between PD-L1+ tumor cells and PD-1+ CD8+ T cells, the intended target for PD-L1/PD-1 checkpoint blockade therapies, is disrupted, the result is reinvigoration of the antitumor CD8+ T cell response and enhanced CD8+ T cell-mediated killing of tumor cells. Here, CD8A is linked to neoplasm.